Overview

About HemaQuest Pharmaceuticals

HemaQuest Pharmaceuticals is a San Diego and Seattle-based biopharmaceutical company focused on developing small molecule therapeutics based on its short chain fatty acid (SCFA) derivative technologies to treat serious and life-threatening orphan hematologic disorders, including sickle cell disease and beta thalassemia as well as viral-related malignancies. The Company currently has one product in clinical development, HQK-1001 for treating sickle cell disease and beta thalassemia.

The Company's investors include De Novo Ventures of Palo Alto, CA; Forward Ventures of San Diego, CA; Lilly Ventures of Indianapolis, IN; Aberdare Ventures of San Francisco, CA, and Latterell Venture Partners of San Francisco, CA.

Media Contact

Tamara A. Seymour, Chief Financial Officer

Email: tseymour@hemaquest.com

or

Jerome Lyons
Telephone: (206) 826-9900
Email: jlyons@hemaquest.com